#14Metabolic & Frontier
AOD-9604
synthetic C-terminal human-growth-hormone fragment
Evidence: human RCTReviewed 2026-07-25
Investigated uses
- Historical obesity development and later neuropathic-pain studies as LAT8881.
Mechanism and hypotheses
- AOD-9604/LAT8881 is an hGH C-terminal fragment with an added N-terminal tyrosine; historical obesity development did not establish clinical weight-loss efficacy.
- Hypothesized: Analgesic development has proposed LANCL1-linked stress-response signaling, but this is not an established clinical mechanism.
Human evidence
- Historical obesity development involved multiple human trials but the later efficacy program did not meet its primary weight-loss endpoint; later LAT8881 trials investigated neuropathic pain. Limitations: Different oral/IV formulations and indications; does not establish efficacy or safety of injectable gray-market AOD-9604.
Safety highlights
- Historical development did not identify a broad safety signal, but FDA cites immunogenicity and impurity concerns for compounded peptide products.
- Route-specific and chronic risks of gray injectable AOD-9604 remain unknown.
Regulatory context
No FDA-approved AOD-9604/LAT8881 drug was identified; FDA lists AOD-9604 among substances raising compounding safety concerns.
Sources used for this entry
- PubMed search: AOD-9604 — PubMed
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration
- Drugs@FDA database — U.S. Food and Drug Administration
- EMA medicines search — European Medicines Agency
- NCT03865953: Oral LAT8881 in neuropathic pain — ClinicalTrials.gov
- NCT05298306: Intravenous LAT8881 proof-of-concept — ClinicalTrials.gov